News

The 23rd Annual meeting of the North American Neuromodulation Society took place in Las Vegas, NV, earlier this month—the last meeting at this venue before it moves to Orlando, FL next year. As one of the largest conferences on the topic of neuromodulation, this event brings together discoveries in basic and clinical neuroscience with innovations in neural engineering. This year the program featured a half-day session called Emerging Technology Forum.

About 85 executives and entrepreneurs took part in the second annual Bioelectronic Medicine Forum held in New York City earlier this month. The agenda featured four discussion panels covering topics like investments, digital health, regulatory and reimbursement, and future technology. More than a dozen entrepreneurs presented their ventures and technology innovations at the event and NBR editor Jam…

About 120 neurotechnology professionals from industry, research, investment, and clinical fields gathered for the 19th annual Neurotech Leaders Forum in San Francisco earlier this month. Discussions ensued from current trends, recent opportunities, and on-going challenges. One of the highlights of this event is the exchange of new ideas and the dialogue with neurotech entrepreneurs. The keynote speakers this year each spoke of finding clues in the human nervous system—but from different perspectives.

As it has in the past, the recent meeting of the North American Neuromodulation Society offered a host of scientific and clinical presentations that meshed nicely with commercial product offerings on the exhibit floor [see conference report, p7]. As we report in our article on page 1 of this issue, one such area of scientific advance that will likely have a tremendous impact on commercial product development is the role that glial cells play in the pain pathway.

The market for treating epilepsy and related seizure disorders stands to expand considerably in coming years. Several recent developments highlight progress in both commercial product development and clinical research. Technological advances in this field include both enhanced neurosensing systems as well as neuromodulation systems. At the American Epilepsy Society meeting earlier this month, Neuro…

The first ever Neurotech Entrepreneurs Workshop, produced , Arizona State University, the University of Houston, and the University of Pittsburgh, was held at the ASU campus on December 13-15, 2019. At the workshop, 20 neurotechnology industry professionals joined 30 future entrepreneurs chosen from a pool of graduate trainees selected to participate . The 30 participants were assigned to one of 10…

The West Virginia University Rockefeller Neuroscience Institute and WVU Medicine announced the launch of a first-in-the-U.S. clinical trial using deep brain stimulation for patients suffering from treatment-resistant opioid use disorder. Funded through a grant from the National Institute on Drug Abuse, the clinical trial is led , executive chair of the RNI, and a multidisciplinary team of neurosurgical, psychiatric, neuroscience, and other experts.

Teijin Ltd., the Japanese pharmaceutical and medical device manufacturer, and NeuroSigma, Inc., the Los Angeles, CA manufacturer of trigeminal nerve stimulation systems, announced entering into a partnership based on an exclusive license agreement that grants Teijin Pharma exclusive rights to NeuroSigma’s TNS patent rights in Japan related to ADHD and to market the Monarch eTNS System for the noninvasive treatment of ADHD in Japan.

As the second decade of the 21st century—and the second decade of our coverage of the neurotechnology industry—comes to a close, it’s worth taking a look back over the last year and putting it in context with the last 10 years. There were many significant commercial developments in 2019, including Neuralink’s public announcement, the emergence of new competitors like Axonics Modulation and Saluda Medical, and mergers such as GTX medical/NeuroRevovery Technologies.

The market for implanted sacral nerve stimulation devices to treat bowel and bladder disorders has become decidedly more competitive in recent weeks. Axonics Modulation Technologies received FDA approval for OAB for its rechargeable system and market-leader Medtronic responded with an announcement of its own rechargeable device and a patent infringement lawsuit against Axonics. Earlier this month, Axonics announced FDA approval of the Axonics r-SNM system for the clinical indications of OAB and urinary retention.